Navigation Links
Tumors with ALK rearrangements can harbor more mutations
Date:4/22/2013

DENVER The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung adenocarcinoma cases harbor KRAS mutation, EGFR mutation, or ALK translocation, and an additional 5 percent or so have been shown to have mutations involving BRAF, PIK3CA, HER2, MET, MEK1, NRAS, and AKT. In the vast majority, these driver mutations are mutually exclusive. But in a recent study published in the International Association for the Study of Lung Cancer's Journal of Thoracic Oncology (JTO) researchers have found that tumors with ALK rearrangements can harbor additional mutations.

Researchers looked at 25 cases of pulmonary adenocarcinoma surgically treated at Mayo Clinic between 1999 and 2007 with ALK gene rearrangement, confirmed by break-apart fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC). Using the DNA extracted from formalin-fixed paraffin-embedded tumor samples, a MassArray-based Lung Cancer Mutations Screening Panel was performed to test for 179 individual mutations in 10 genes, with positive results confirmed by sequencing.

They found additional mutations in 5 of 25 (20 percent) of ALK positive cases. Four of these were point mutation in the MET gene that are of unknown clinical significance, since they may represent germline polymorphisms. However, one case had an EGFR mutation, further supporting that EGFR mutations can be present in ALK rearranged tumors, although it is rare.

"Much is yet to be learned about treatment of patients with both ALK rearrangement and EGFR mutation," the authors report. "Although some of these patients have had a good response to the EGFR inhibitors erlotinib and gefitinib, one patient reportedly showed resistance to erlotinib. Further research is needed to determine if patients with coexisting EGFR mutation and ALK gene rearrangement may have altered response to EGFR or ALK inhibitors. This will be important to determine whether these drugs should be used in a synchronous or sequential fashion to achieve maximum benefit."


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Wayne State researchers seek calcium channels to target cancer tumors
2. Hundreds of alterations and potential drug targets to starve tumors identified
3. Hundreds of alterations and potential drug targets to starve cancer tumors identified
4. Chemical shift MRI helps differentiate renal cell tumors more likely to metastasize
5. Virus-like particles provide vital clues about brain tumors
6. Freezing Treatment May Help Destroy Lung Tumors: Study
7. Electrical pulse treatment pokes holes in hard-to-treat tumors
8. AACR: Positive data supports advancing BIND-014 to phase 2 clinical trials for solid tumors
9. Some patients with incurable tumors and BRCA mutations respond to new 2-drug combination
10. Different drug combinations work best for prevention versus treatment of colorectal tumors
11. Engineered T cells kill tumors but spare normal tissue in an animal model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... Freedom, PA (PRWEB) , ... April 22, 2017 ... ... healthcare experience to his role as Vice President of Sales and Business Development ... of key GPO/IDN business partner engagements, business development, and strategic planning for the ...
(Date:4/21/2017)... ... April 21, 2017 , ... The staff at Palm Beach Face is proud to announce ... the 2017 London Marathon. Set to take place on April 23rd, the London Marathon has ... Schwartz will run as part of team EMPOWER, raising money for the international charity, Smile ...
(Date:4/21/2017)... Wis. (PRWEB) , ... April 21, 2017 , ... ... today announced that its B-595 and B-7569 vinyl label materials ... identification and warning labels are tested to remain intact and legible, for use on ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of ... with the 2017 Ruth Ravich Patient Advocacy Award in recognition of her ... was honored with the award at The Beryl Institute’s annual Patient Experience Conference ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 ... treating and preventing substance use disorders. , The mission of AWARE is ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence that ... Parkinson,s, according to a study released today that will be ... Meeting in Boston , April 22 ... the treatment of Parkinson,s disease, the oral drug levodopa has ... and longevity. But as the disease progresses, the effects of ...
(Date:4/19/2017)... OAKS, Calif. , April 19, 2017 /PRNewswire/ ... industrial buildings it is developing at Conejo Spectrum ... , to Atara Biotherapeutics, Inc. , ... with severe and life-threatening diseases that have been ... on allogeneic T-cell therapies for cancer, autoimmune and ...
Breaking Medicine Technology: